Avacta Group geared up to bring high quality, high volume lateral flow antigen test to market (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss its partnership with Mologic. Alastair talks us through the details of the agreement, expands on the additional manufacturing capacity, explains how it will develop develop other diagnostic tests including a second generation COVID test and tells us when we can expect an update in respect of the clinical evaluation of the lateral flow test.

Avacta Group is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Avacta Group Plc

More articles like this

Avacta Group Plc

Summer launch target for Avacta coronavirus diagnostic test

A transatlantic alliance between Avacta in Cambridge UK and Adeptrix  in Massachusetts has accelerated progress of a new diagnostic test for coronavirus. A BAMS™ (bead-assisted mass spectrometry) diagnostic test for the COVID-19 infection being developed by

Avacta Group Plc

Avacta Group Proposed fundraising to raise up to £45 million

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced in response to substantial institutional interest, its intention to raise gross proceeds of up to £45 million by means of a placing  to institutional and

Avacta Group Plc

Avacta Group announces offers for subscription via PrimaryBid

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced offers for subscription via PrimaryBid of new ordinary shares of 10p each in the Company at an issue price of 120 pence per New Ordinary Share, being

Avacta Group Plc

Avacta Group AGM to be held on Monday 22nd June 2020

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that its Annual Report and Accounts for the period ended 31 December 2019 and the Notice of the 2020 Annual General Meeting are

Avacta Group Plc

SARS-COV-2 Neutralising Affimer Reagents video presentation

Alastair Smith gives a video presentation on their recent announcement – SARS-COV-2 Neutralising Affimer Reagents: Potential for a COVID-19 Affimer Therapy. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications

Avacta Group Plc

Avacta Group “Affimers First-Class Prospects” says Zeus Capital

Avacta Group PLC (LON:AVCT) is leveraging the antibody-like properties of Affimers for Therapeutic and Diagnostic applications across multi-billion dollar markets, including testing and treatment for COVID-19, building a differentiated pipeline and global partnerships. The near-term key

Avacta Group Plc

Affimer technology

Developing the next generation of biotherapeutics Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A. Avacta is building a pipeline of clinically differentiated cancer immunotherapies leveraging the key

Avacta Group Plc

Avacta Group ships Affimer reagents for COVID-19 antigen testing

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners. The Group recently reported that it had generated